Background and Aims Corona virus disease‐19 (COVID‐19) is a recently discovered infection that transmitted briskly worldwide. In this disease (COVID‐19), it was discovered that several disorders, such diabetes, increased the severity and fatality rate. Until now, studies investigating the correlation between diabetes and COVID‐19 in Sudan have not yet been conducted. Thus we aimed to evaluated the characteristics and outcomes of COVID‐19 among diabetic patients Methods A prospective study included 70 diabetic patients with COVID‐19 in Wad‐Medani Isolation Center from September to December 2020. Data concerning demographics and clinical characteristics, as well as outcomes were collected. Results Out of 70 patients, 46 (66%) were men and 24 (34%) were women; the average age was 63 ± 12 years. In diabetes mellitus (DM) types, 69 (98.6%) patient were T2DM. The average of DM duration was 10 ± 6.2 years. Insulin was the major DM medication used by more one‐half of study patients ( n = 37; 52.9%). Newly discovered DM after COVD‐19 infection was encountered in 5 (7.1%) patients. Most of the study subjects ( n = 44; 63%) had moderately severe form of disease. Hypertension was the commonest comorbid in 29 (41.4%) patients. The intensive care unit admission rate among our study group was 10% ( n = 7). The mortality rate among our study patients was found to be 11.4% ( n = 8). Dead patients were significantly had high HbA1c levels (11.6 ± 7% vs. 8.8 ± 5%; p = 0.001). Additionally, all individuals with a severe COVID‐19 illness ( n = 6; 100%) were dead comparing to no patient died with mild covid illness and 4.5% patients with moderately severe infection ( p < 0.001). Conclusion The majority of COVID‐19 diabetic patients were males and older in age. Most of the patients presented with moderate severity and moderately uncontrolled DM. Hypertension was the major comorbidity. The mortality rate was as high as 11.4% and associated with high HbA1c levels and severe form of COVID‐19 as well.
Background: The novel coronavirus (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December of 2019 in the city of Wuhan, China. In addition to respiratory symptoms, reports are emerging of neurological manifestations of SARS‐CoV‐2 Objective: To assess the neurological manifestations in COVID-19 positive patients. Methods: A cross sectional, prospective, descriptive, hospital based study included 106 COVID-19 patients in Gezira COVID-19 Centre during the period from June to September 2020. Data regarding demographics, clinical history, presentations, laboratory investigations, neuroimaging and outcomes were collected. Results: 106 COVID-19 patients were included in this study, 67(63.2%) were males and 39(36.8%) were females, their mean age was 68±4.3 years and most of them 58(54.7%) aged above 60 years. The main respiratory symptoms of COVID 19 were dyspnea in 66(62.3%), fever in 59(55.7%), cough in 50(47.2%) patients. The non specific neurological symptoms of COVID-19 were headache in 29(27.4%), dizziness in 9(8.5%) and syncope in one (0.9%) patient. Symptoms of COVID-19 related to cranial nerves such as change in smell (n= 87; 82.1%) and dyskinesia (n=80; 75.4%) were the most common neurological manifestations encountered. Focal neurological deficits were TIA in 2(1.9%), intracranial hemorrhage in one (0.9%) and transverse myelitis in one (0.9%) patient. Conclusion: The study showed that neurological manifestations of COVID-19 were common and mostly olfactory and gustatory dysfunctions among Sudanese subjects. Also, COVID-19 could be a risk factor for stroke and transverse myelitis. The study suggest that objective olfactory and gustatory may be needed to determine their clinical significance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.